京漢股份(000615.SZ)擬1.82億元出售通遼京漢100%股權
格隆匯1月13日丨京漢股份(000615.SZ)公佈,2020年1月10日,公司全資子公司京漢置業集團有限責任公司(以下簡稱"京漢置業")與北京京台企業管理諮詢有限公司(以下簡稱"北京京台")簽署了《股權轉讓協議》,京漢置業將其持有的通遼京漢置業有限公司(以下簡稱"目標公司"或"通遼京漢")100%的股權轉讓給北京京台,轉讓金額為1.82億元。
此次交易符合公司實際經營及未來發展需要,有利於優化公司資產結構,符合公司戰略轉型方向,有助於公司聚焦新材料及綠色纖維轉型業務,促進公司長遠發展。此次股權轉讓事項完成後,公司不再持有通遼京漢股權,通遼京漢將不再納入公司合併報表範圍。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.